Dec 17 (Reuters) – Johnson Matthey (JMAT.L) reported on Friday it will sell its wellbeing business enterprise to investment decision firm Altaris Funds Partners for an company price of about 325 million pounds ($432.71 million), as the substances maker plans to refocus on its main assets.

The London-detailed business claimed it would keep a 30% stake in the health and fitness organization, which develops and manufactures professional and intricate energetic pharmaceutical elements.

Johnson Matthey, which commenced a review of the division 8 months in the past, claimed it would get an impairment strike of 200 million lbs from the sale expected to close by mid-2022.

The news arrives after the organization announced past month that it was selling its battery resources and glass systems firms, even though it delivers in Bayer AG’s (BAYGn.DE) Liam Condon as its new boss in March.

The British enterprise, which tends to make car or truck pollution filters and designs to aim on areas these as hydrogen technologies, explained it would redeploy about 150 million lbs of cash expenditure beforehand earmarked for the non-main health division to higher expansion businesses.

($1 = .7511 lbs)

Reporting by Muhammed Husain and Yadarisa Shabong in Bengaluru Editing by Sriraj Kalluvila and Sherry Jacob-Phillips

Our Specifications: The Thomson Reuters Trust Concepts.